Original Article

Natural history of six neonates with severe MTM1-related X-linked myotubular myopathy

  • HU Xiangsong ,
  • LIN Yating ,
  • ZHU Tianwen
Expand
  • 1. Department of Neonatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    2. Department of Neonatology, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200062, China
    3. Department of Pediatrics, Anqing First People's Hospital, Anhui Medical University, Anqing 246000, Anhui, China

Received date: 2025-09-18

  Accepted date: 2025-12-08

  Online published: 2026-02-02

Abstract

Objective X-linked myotubular myopathy (XLMTM) caused by MTM1 gene variation is a rare neuromuscular disease. Currently, the systematic summary of the early natural history and diagnostic clinical characteristics of XLMTM patients in China is still incomplete. Methods We retrospectively reviewed clinical data, including perinatal findings, neonatal phenotype, genetic results, and outcomes, of male neonates with genetically confirmed severe XLMTM who were admitted to the neonatal intensive care units (NICUs) in two hospitals, between January 2018 and August 2024. And the early life natural history of this disease was systematically summarized. Results Six male patients were included in this cohort. The average gestational age was (37.5±2.6) weeks. Three cases were indicated with polyhydramnios by prenatal ultrasonography, one case was found with a racquet-shaped placenta at 24 weeks of gestation, and two cases had a family history of multiple early deaths among male infants within the same lineage. Neonatal asphyxia occurred immediately after birth in 6 children, with Apgar scores ranging from 3 to 6 at 1 minute and 4 to 7 at 5 minutes. All the patients presented with severe neonatal respiratory failure and characteristic profound hypotonia/floppy, and required continuous mechanical ventilation, nutritional support and nasogastric feeding throughout the course. All the patients had secondary hole-type atrial septal defect (ASD type II), with defect diameters ranging from 2.0 to 4.5 mm. Associated findings included cryptorchidism, micrognathia and slender limbs. All patients died within 6 months, with a median survival of 32 (3-150) days. The leading causes of death included respiratory failure, infection, and withdrawal of care. Genetic analysis revealed five maternally inherited variants and one de novo mutation in the MTM1 gene; five variants were located in the Rac1-induced recruitment domain (RID), and one in the protein tyrosine phosphatase (PTP) catalytic domain. Conclusions Severe XLMTM neonates exhibit a highly uniform clinical phenotype. The core features of its natural history, including neonatal asphyxia, respiratory failure, characteristic profound hypotonia, specific dysmorphic features and limb anomalies, serve as key diagnostic pointers. This cohort suggests that the natural history of XLMTM neonates in China may differ from international reports, and different types of MTM1 gene variations can all lead to extremely severe phenotypes. Given that most patients show early warning signs such as polyhydramnios during the perinatal period, and the disease progresses rapidly with an extremely poor prognosis, the importance of early genetic screening and diagnosis for high-risk pregnant women and their fetuses is underscored.

Cite this article

HU Xiangsong , LIN Yating , ZHU Tianwen . Natural history of six neonates with severe MTM1-related X-linked myotubular myopathy[J]. Journal of Clinical Pediatrics, 2026 , 44(2) : 124 -131 . DOI: 10.12372/jcp.2026.25e1158

References

[1] Laporte J, Hu LJ, Kretz C, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast[J]. Nat Genet, 1996, 13(2): 175-182.
[2] Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy[J]. Orphanet J Rare Dis, 2008, 3: 26.
[3] Lawlor MW, Dowling JJ. X-linked myotubular myopathy[J]. Neuromuscul Disord, 2021, 31(10): 1004-1012.
[4] Beggs AH, Byrne BJ, De Chastonay S, et al. A multicenter, retrospective medical record review of X-linked myotubular myopathy: the recensus study[J]. Muscle Nerve, 2018, 57(4): 550-560.
[5] Martin C, Servais L. X-linked myotubular myopathy: an untreated treatable disease[J]. Expert Opin Biol Ther, 2025, 25(4): 379-394.
[6] Wang CH, Dowling JJ, North K, et al. Consensus statement on standard of care for congenital myopathies[J]. J Child Neurol, 2012, 27(3): 363-382.
[7] 胡勇, 黄希. 新发突变基因的新生儿X-连锁肌小管肌病1例并文献回顾[J]. 中南大学学报(医学版), 2024, 49(3): 491-496.
  Hu Y, Huang X. Neonatal X-linked myotubular myopathy with a de novo mutation: A case report and literature review[J]. Zhongnan Daxue Xuebao (Yixueban), 2024, 49(3): 491-496.
[8] 付杰, 徐承琴, 郑爱华, 等. MTM1基因半合子突变致新生儿X连锁中央核肌病1例[J]. 浙江医学, 2024, 46(22): 2433-2435.
  Fu J, Xu CQ, Zheng AH, et al. A case of neonatal X-linked centronuclear myopathy caused by a hemizygous mutation in the MTM1 gene[J]. Zhejiang Yixue, 2024, 46(22): 2433-2435.
[9] 王钿钿, 王瑜, 王化彬. MTM1基因半合子突变及RYR1基因杂合突变致新生儿X-连锁肌管肌病2例临床分析[J]. 中华实用诊断与治疗杂志, 2023, 37(7): 722-726.
  Wang TT, Wang Y, Wang HB. Clinical analysis of two cases of neonatal X-linked myotubular myopathy caused by hemizygous mutation of MTM1 gene and heterozygous mutation of RYR1 gene[J]. Zhonghua Shiyong Zhenduan Yu Zhiliao Zazhi, 2023, 37(7): 722-726.
[10] 洪先慧, 李海英, 吴尤佳. MTM1基因突变致新生儿肌管性肌病1例[J]. 儿科药学杂志, 2023, 29(2): 64-66.
  Hong XH, Li HY, Wu YJ. A case of neonatal myotubular myopathy caused by MTM1 gene mutation[J]. Erke Yaoxue Zazhi, 2023, 29(2): 64-66.
[11] 谢添, 葛佳静, 张子明, 等. MTM1基因变异致5例新生儿中央核肌病的临床及遗传学分析[J]. 中国当代儿科杂志, 2025, 27(9): 1071-1075.
  Xie T, Ge JJ, Zhang ZM, et al. Clinical and genetic features of 5 neonates with centronuclear myopathy caused by MTM1 gene variation[J]. Zhongguo Dangdai Erke Zazhi, 2025, 27(9): 1071-1075.
[12] Dowling JJ, Lawlor MW, Das S. X-Linked Myotubular Myopathy. 2002 Feb 25 [updated 2018 Aug 23]. In: Adam MP, Bick S, Mirzaa GM, et al, editors. GeneReviews? [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.
[13] Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)[J]. Genet Med, 2020, 22(2): 245-257.
[14] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
[15] Annoussamy M, Lilien C, Gidaro T, et al. X-linked myotubular myopathy: a prospective international natural history study[J]. Neurology, 2019, 92(16): e1852-e1867.
[16] Amburgey K, Tsuchiya E, de Chastonay S, et al. A natural history study of X-linked myotubular myopathy[J]. Neurology, 2017, 89(13): 1355-1364.
[17] Darras BT, De Vivo DC. Precious SMA natural history data: a benchmark to measure future treatment successes[J]. Neurology, 2018, 91(8): 337-339.
[18] Bhattacharyya T, Ghosh A, Verma S, et al. Structural rationale to understand the effect of disease-associated mutations on Myotubularin[J]. Curr Res Struct Biol, 2023, 5: 100100.
[19] McEntagart M, Parsons G, Buj-Bello A, et al. Genotype-phenotype correlations in X-linked myotubular myopathy[J]. Neuromuscul Disord, 2002, 12(10): 939-946.
[20] Fattori F, Maggi L, Bruno C, et al. Centronuclear myopathies: genotype-phenotype correlation and frequency of defined genetic forms in an Italian cohort[J]. J Neurol, 2015, 262(7): 1728-1740.
[21] Shieh PB, Kuntz NL, Dowling JJ, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial[J]. Lancet Neurol, 2023, 22(12): 1125-1139.
[22] Lawlor MW, Schoser B, Margeta M, et al. Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial[J]. EBioMedicine, 2024, 99: 104894.
[23] Andreoletti G, Romano O, Chou HJ, et al. High-throughput transcriptome analyses from ASPIRO, a phase 1/2/3 study of gene replacement therapy for X-linked myotubular myopathy[J]. Am J Hum Genet, 2023, 110(10): 1648-1660.
[24] Voermans NC, Ferreiro A, Aartsema-Rus A, et al. Gene therapy for X-linked myotubular myopathy: the challenges[J]. Lancet Neurol, 2023, 22(12): 1089-1091.
[25] Wilson JM, Flotte TR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy[J]. Hum Gene Ther, 2020, 31(13-14): 695-696.
[26] Ross LF, Clarke AJ. A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States[J]. Pediatr Neurol, 2017, 77: 12-22.
[27] Dangouloff T, Boemer F, Servais L. Newborn screening of neuromuscular diseases[J]. Neuromuscul Disord, 2021, 31(10): 1070-1080.
[28] Dangouloff T, Lang H, Benmhammed N, et al. Newborn screening and rapid genomic diagnosis of neuromuscular diseases[J]. J Neuromuscul Dis, 2025, 12(2): 157-172.
[29] Tanner SM, Laporte J, Guiraud-Chaumeil C, et al. Confirmation of prenatal diagnosis results of X-linked recessive myotubular myopathy by mutational screening, and description of three new mutations in the MTM1 gene[J]. Hum Mutat, 1998, 11(1): 62-68.
[30] De Rycke M, Berckmoes V. Preimplantation genetic testing for monogenic disorders[J]. Genes (Basel), 2020, 11(8): 871.
[31] Luglio A, Maggi E, Riviello FN, et al. Hereditary neuromuscular disorders in reproductive medicine[J]. Genes (Basel), 2024, 15(11): 1409.
Outlines

/